The prevalence of atrial fibrillation (AF) is increasing owing to the demographics of aging Western societies.
Introduction
The prevalence of atrial fibrillation (AF) is increasing owing to the demographics of aging Western societies.
In patients below the age of 55 years the prevalence of AF is 0.1%, but this increases to 9% in patients over 80 years of age [1] . Stroke is the most devastating complication of AF and occurs at an annual rate of 5% in nonanticoagulated patients [2] . Hence, stroke prevention is an essential part of the management of AF. Oral anticoagulation (OAC) with either warfarin or non-vitamin K anticoagulants (novel oral anticoagulants: NOACs) reduces the risk of stroke by 65%, but it comes at the price of an annual rate of major bleeding complications of up to 5% [3] .
In over 90% of AF patients, thrombi can be detected in the left atrial appendage (LAA), which is the the rationale for LAA occlusion (LAAO) [4] as an alternative therapy for stroke prevention in AF patients. Several devices have been used ( fig. 1 ).
The most commonly used percutaneous devices for LAAO are the Amplatzer (St. Jude Medical, St. Paul, MN) and the Watchman (Boston Scientific, Marlborough, MA) devices. Historically, the PLAATO device (ev3 Inc, Plymouth, MN) was the first available percutaneous device for LAAO, but was removed from the market because of economic considerations [5, 6] . The gap was filled by off-label use of nondedicated Amplatzer devices used primarily for the occlusion of patent foramen ovale (PFO), atrial septal defects (ASDs) or ventricular septal defect (VSDs) [7] . These nondedicated devices served the purpose of stroke prevention, but came along with a relatively high embolisation rate (12%) [8] . In 2008, a dedicated Amplatzer device became available (AMPLATZER Cardiac Plug [ACP]), which reduced device embolisations to 2%. Still, given the intricacy of the procedure, the rate of procedural complications remains relatively high (9.8%) and the procedure has a relatively flat learning curve [8] [9] [10] . The Watchman device is another widely used dedicated LAA occluder. In a landmark randomised study with this device (PROTECT-AF) [2] , patients were randomised to a vitamin K antagonist (VKA) or LAAO. At 1 year, LAAO
Summary
Objectives: To report our 5-year single centre experience with percutaneous left atrial appendage occlusion (LAAO).
Background: LAAO evolved rapidly at our institution, as it has worldwide.
The procedure requires experience to be safely performed. We evaluated indications, and short-and long-term outcome of LAAO.
Methods: LAAO was performed either (a) under general anaesthesia with transesophageal echocardiographic and fluoroscopic guidance, (b) under local anaesthesia with intracardiac echocardiographic and fluoroscopic guidance, or (c) with fluoroscopic guidance alone, depending on operator preference. A previously detected patent foramen ovale (PFO) or atrial septal defect (ASD) was used for left atrial access by one operator (FN) with Amplatzer devices only; transseptal puncture was routine in the rest. Patients were discharged on acetylsalicylic acid and clopidogrel for 1-6 months; oral anticoagulation (OAC) was stopped the day of the procedure.
Results: From June 2010 to November 2015, LAAO was performed in 284 patients at the University Heart Centre Zurich, of whom 247 were included in the analysis (164 males, 77 ± 8.9 years, CHA2DS2-Vasc-score 4.5 ± 1.4, HAS-BLED-score 3.6 ± 1.1). Devices used were the Amplatzer Cardiac Plug in 107 patients (42.9%), the Amplatzer Amulet in 87 patients (35.2%) and the Watchman device in 53 patients (21.5%). A PFO or ASD was used for left atrial access and occluded after LAAO in 20 (8.1%) patients. Procedures were performed with coronary angiography in 72 patients (29.2%), after a percutaneous coronary intervention in 36 patients (14.6%), with transcatheter aortic valve implantation in 56 patients (22.7%) and with a MitraClip procedure in 14 patients (5.7%). Periprocedural major adverse events (procedural death, stroke, tamponade with need for percutaneous drainage or surgical bailout, major or life-threatening vascular complication, kidney injury grade proved to be noninferior to VKAs for the primary endpoint of stroke, cardiovascular or unexpected death and systemic embolism. In the intervention group, adverse safety events were more frequent, mostly procedure-related pericardial tamponade and periprocedural strokes, again underlining the intricacy of the procedure. With increasing operator experience, procedural adverse safety events were considerably reduced [11] .
However, it took almost 4 years of follow-up to neutralise the initial procedure-related events by fewer adverse thrombotic events thereafter. This translated into superiority of LAAO over VKAs for stroke, systemic embolism and cardiovascular death. Of note, mortality was significantly reduced by 40% in the LAAO group as compared with VKAs [12] . It can therefore be speculated that with longer follow-up survival curves might further diverge, resulting in an even more pronounced benefit of LAAO. Besides offering an effective treatment option, LAAO proved to be more cost effective than VKAs and even more so than NOACs [13] .
We report our institutional experience with LAAO at the University Heart Centre Zurich, Switzerland over a period of more than 5-years, including different operators and different approaches to LAAO.
Methods

Patients
This was a retrospective single-centre registry study of all patients undergoing LAAO at the University Heart Centre Zurich between June 2010 and November 2015.
Indications for LAAO included AF with CHA2DS2-VASc 
Follow-up
After 3-6 months, a follow-up TEE was performed to verify correct device position and to exclude relevant residual leaks into the LAA or thrombi on the device. If TEE was not feasible, follow-up TTE or computed tomography (CT) was used instead. 
Endpoints
Statistical analysis
Continuous variables are expressed as mean ± standard deviation (SD) or median and interquartile range (IQR). Between-group comparisons were made using one-way analysis of variance or student's t-test, as appropriate. Categorical data are presented as frequency (percentages) and were compared with use of the Fisher exact or the chi-square test. All probability values and confidence intervals were two-sided. A probability value of <0.05 was considered significant, and all tests were two-tailed. All analyses were performed with SPSS version 21.0 software (SPSS Inc., Chicago, IL). 
Results
Patient characteristics
Procedural outcome
Since 2010 LAAOs were performed of which only 95 were included in the study. In 8.2% (20 patients), the LAA was reached using a PFO or ASD, which was subsequently occluded using a PFO or ASD occluder. The PFO and ASD closures were uneventful; the same sheath and delivery system as for the LAA occlusion (TorqVue 45 × 45 sheath) were used.
LAAO devices
Mean duration of hospitalisation was 7.4 ± 7.0 days. In patients with isolated LAAO (not combined interventions) median hospitalisation was 3 days; IQR 2-6 days.
Seventeen patients (6.9%) were discharged the day of intervention and 57 patients (23.1%) the day after the intervention. For patients referred for isolated LAAO on an elective basis, same day discharge or discharge the day after the procedure is routine at our institution.
Patients were discharged on ASA indefinitely (88.3%;
218 patients) and a thienopyridine for either 3 (22.7%; 56 patients), 6 (25.5%; 63 patients) or 12 months (15.8%; 39 patients).
Follow-up
Clinical follow-up was complete in 89.9% (222 patients) after a mean duration of 10 ± 9.6 months. Overall, 9.9%
(22 patients) died during follow-up (after a median of 3 months; IQR 1-5 months). The deaths included cardiac deaths of seven patients, which were due to heart failure in three and ventricular tachycardia and/or fibrillation in two, with one each due to stroke or endocarditis (occurring after an Enterococcus faecalis positive urinary tract infection 7 months after the intervention). Ten deaths were non-cardiac in nature, one due to bleeding and five of unknown cause ( fig. 6 ).
Of all deaths, one due to stroke was related to LAAO. In this case the patient died as a result of a cerebrovascular event (major stroke) occurring 2 weeks after successful LAAO in conjunction with transcatheter aortic valve implantation. Upon presentation of the patient with a major stroke, TEE showed mobile thrombus on the disc of the device as the most likely source of embolism. Three cerebrovascular events (1.4%) occurred during follow-up. In two of these patients a control TEE showed no thrombus on the device; the third patient is tient a leak ≥5 mm was detected between the warfarin ridge and the device, which is considered a harmless form of a leak without perfusion of the distal lobes of the LAA -the patient remains asymptomatic and the leak had closed at 1-year follow-up TEE. If a mobile thrombus was found on the device rivaroxaban therapy was initiated, clopidogrel and ASA were discontinued, and TEE repeated 4-6 weeks later, at which point rivaroxaban was terminated and ASA restarted.
Correct device position could not be confirmed in one patient, where the device was found in the abdominal aorta at follow-up 6 months after implantation. Retrospectively, device embolisation occurred within 24-hours of the procedure, but was missed at discharge. The device was snared and externalised. As the patient did not wish implantation of another device, medical therapy with rivaroxaban was re-initiated [15] .
Discussion
This study, based on a large single centre experience, The study population comprised patients at high risk for stroke and bleeding. The average CHA2DS2-Vasc score was 4.5 and a HAS-BLED score of 3.6. Assuming a 65% risk reduction in the occurrence of cerebrovascular accidents with VKAs, the stroke rate after 10 months with VKA therapy would be 1.5%, a value comparable to the observed stroke rate in this registry. On the other hand, major bleeding complications were exceedingly infrequent and were reduced 3.8-fold as compared with the expected rate of 5.5% at 10 months (according to the HAS-BLED score) ( fig. 7) .
Combined interventions are routine in our institution and performed in 62% of the patients. As such combined procedures are inherently associated with an increased risk, this fact negatively influenced the overall periprocedural adverse event rate (table 5) Based on current experience, protrusion of the disc of the Amplatzer occluder into the neck of the LAA is not considered dangerous and does not seem to require any action [21, 22] . This supports the theory that it is mostly the trabeculated lobes that are thrombogenic and not the smooth wall of the LAA neck.
As LAAO is a technically demanding intervention, operator experience is crucial. As already shown in the PREVAIL study, procedural success increased and pro- 
Limitations
The manuscript describes a retrospective analysis of a large cohort of patients and therefore is more of a descriptive nature, with the inherent limitations of such a retrospective analysis. Some procedural data were not collected, such as amount of contrast or x-ray dose.
There was no core laboratory analysis of the echocardiographic data.
Conclusion
In experienced, high volume centres LAAO can be performed with a high procedural success rate and a low complication rate. Nevertheless, LAAO is a complex procedure with potentially important complications that can kept at a low level only after an important learning curve. Under these conditions, LAAO is a valuable alternative to oral anticoagulation in stroke prevention. Importantly, the procedure, if successfully performed, markedly reduces the bleeding risk that is associated with any type of oral anticoagulation. Thus, LAAO should therefore specifically be considered as first-line therapy for stroke prevention in patients at high risk of bleeding, on triple anticoagulation and with a high risk of falls, but may also be offered as an option to all patients suffering from atrial fibrillation after proper informed consent. or only single antiplatelet therapy (MAPT) was prescribed.
